Through its B2C division, i-Health, dsm-firmenich plans to increase access to Lactéol, which is the over-the-counter postbiotic supplement of Adare Biome for settling gut upsets
dsm-firmenich acquires postbiotics firm Adare Biome. (Credit: dsm-firmenich)
US-based Adare Pharma Solutions has completed the sale of its Adare Biome business unit to dsm-firmenich, a nutrition, health, and beauty company, at an enterprise value of €275m.
Adare Biome is engaged in the development and production of postbiotics.
Through its business to consumer (B2C) division, i-Health, dsm-firmenich plans to increase access to Lactéol, which is the over-the-counter postbiotic supplement of Adare Biome for settling gut upsets.
Adare Pharma Solutions said that the opportunities for the further development of postbiotic business to business (B2B) components will be found in the fields of dietary supplements, medical nutrition, early-life nutrition, and nutrition for under-nourished people.
dsm-firmenich health, nutrition and care president Philip Eykerman said: “We are excited to welcome the Adare Biome people to the dsm-firmenich family and about the new opportunities this move will unlock.
“dsm-firmenich’s strong global presence and reach in local markets will enable us to deliver Adare Biome products to customers in a faster, more efficient way to bring the proven benefits of postbiotics to a wider range of people around the world.”
The acquisition of Adare Biome is expected to boost dsm-firmenich’s position in the microbiome management market for pets and will broaden its animal health portfolio. The stability of postbiotics can also help to incorporate them into premix feed solutions, said Adare Pharma Solutions.
Adare Pharma Solutions CEO Tom Sellig said: “dsm-firmenich is the ideal company to take Adare Biome to the next level and realise the growth potential of postbiotics.
“They have the infrastructure, together with strong commercialisation and science capabilities, to scale the significant scientific research that we’ve achieved over the years.
“This divestiture will provide Adare Pharma Solutions with additional resources for our core CDMO business and allow us to further grow our position as a world-class outsourcing partner to the pharmaceutical industry.”